Bristol-Myers Squibb

What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Drugs
Seeking Alpha
Fri, 12/6/13 - 10:30 am
JNJ
Gilead Sciences
hepatitis C
sofosbuvir
Olysio
AbbVie
Bristol-Myers Squibb
Merck
Large Study Finds Favorable Risk-Benefit Profile For The New Anticoagulants
Forbes
Thu, 12/5/13 - 06:45 pm
bloodthinners
Pradaxa
Boehringer Ingelheim
Xarelto
JNJ
Eliquis
Pfizer
Bristol-Myers Squibb
edoxaban
Daiichi Sankyo
Pfizer And GlaxoSmithKline: Aiming For Melanoma Cure Supremacy
Seeking Alpha
Thu, 12/5/13 - 06:43 pm
Pfizer
GSK
melanoma
Bristol-Myers Squibb
AstraZeneca
Daiichi Sankyo
Novartis
Yervoy
palbociclib
Mekinist
Zelboraf
Breast Cancer Drug Data Boosts Puma Biotechnology
Investors.com
Thu, 12/5/13 - 12:01 pm
Puma Biotechnology
breast cancer
neratinib
Taxol
Bristol-Myers Squibb
Roche
Herceptin
How The Global Pharma Industry Will Shape Up In The Next 5 Years?
Seeking Alpha
Wed, 12/4/13 - 11:38 am
Bristol-Myers Squibb
GSK
JNJ
Ophthotech
Novartis
Regeneron
Roche
Sanofi
Johnson & Johnson Vs. Pfizer, Bristol In The Race Of Anticoagulants
Seeking Alpha
Tue, 12/3/13 - 11:01 am
JNJ
bloodthinners
Pfizer
Bristol-Myers Squibb
Eliquis
Xarelto
Merck Faces Off Against Bristol-Myers' Yervoy
Motley Fool
Mon, 12/2/13 - 05:00 pm
Yervoy
Bristol-Myers Squibb
MK-3475
melanoma
2014 FDA Drug Approval Decision Calendar
TheStreet.com
Wed, 11/27/13 - 08:39 am
FDA
drug approvals
GSK
Gilead
Theravance
Auxilium
Amarin
Bristol-Myers Squibb
Biogen Idec
Pozen
Vanda
Chelsea Therapeutics
pSivida
Alimera
United Therapeutics
Biomarin
JNJ
Pharmacyclics
Celgene
MannKind
Santarus
AstraZeneca
Durata Therapeutics
Eli Lilly
Omeros
BioDelivery Sciences
Anacor
Keryx
Cubist Pharmaceuticals
Nektar
AstraZeneca: A Positive Future Awaits This Company
Seeking Alpha
Tue, 11/26/13 - 04:48 pm
AstraZeneca
Bristol-Myers Squibb
Xigduo
diabetes
Dapagliflozin
3 Can't-Miss FDA Actions Coming in December
Motley Fool
Tue, 11/26/13 - 04:42 pm
FDA
Gilead Sciences
sofosbuvir
Forxiga
AstraZeneca
Bristol-Myers Squibb
GSK
Anoro Ellipta
Theravance
The Race For A Cure For Cancer
Seeking Alpha
Thu, 11/21/13 - 12:09 pm
cancer
Merck
Bristol-Myers Squibb
Roche
Peregrine Pharmaceuticals
What the End of Bristol-Myers Squibb Royalties Means for Repligen
Motley Fool
Sat, 11/16/13 - 01:26 pm
Bristol-Myers Squibb
Repligen
3 Profitable Pharmaceutical Stocks To Consider As Congress Debates Drug Bill
TheStreet.com
Fri, 11/15/13 - 11:54 am
Forest Labs
Allergan
Bristol-Myers Squibb
What the End of Bristol-Myers Squibb Royalties Means for Repligen
Motley Fool
Fri, 11/15/13 - 11:51 am
Repligen
Bristol-Myers Squibb
Orencia
[video]Bristol-Myers Squibb's Radical Transformation
Motley Fool
Wed, 11/13/13 - 08:47 am
Bristol-Myers Squibb
A Busy Day of Layoffs in Pharma
Motley Fool
Fri, 11/8/13 - 12:00 pm
layoffs
Novartis
Bristol-Myers Squibb
Ariad Pharmaceuticals
After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?
Fierce Pharma
Fri, 11/8/13 - 11:11 am
AstraZeneca
Bristol-Myers Squibb
diabetes
Bristol-Myers Ends Some Discovery Work And Cuts R&D Jobs
Pharmalot
Fri, 11/8/13 - 09:13 am
R&D
Bristol-Myers Squibb
layoffs
Neuroscience? It's Too Risky To Discover Drugs For That
Forbes
Fri, 11/8/13 - 09:11 am
Bristol-Myers Squibb
R&D
Neuroscience
Which Big Pharma Is Poised to See Long-Term Gains?
Motley Fool
Thu, 11/7/13 - 11:00 am
Bristol-Myers Squibb

Pages